RG2133 (2',3',5'-Tri-O-Acetyluridine) in Mitochondrial Disease

This study has been terminated.

First Received: May 7, 2003 Last Updated: August 4, 2005 History of Changes

Sponsor:	Repligen Corporation
Information provided by:	Repligen Corporation
ClinicalTrials.gov Identifier:	NCT00060515

Purpose

The objective of the study is to determine the safety and tolerability of RG2133 in patients with Mitochondrial Disease.

Condition	Intervention	Phase
Mitochondrial Diseases	Drug: RG2133 (2',3',5'-tri-O-acetyluridine)	Phase I

Study Type:	Interventional
Study Design:	Treatment, Non-Randomized
Official Title:	An Open-Label Dose-Escalation Phase I Study to Asses the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RG2133 (2',3',5'-Tri-O-Acetyluridine) in the Treatment of Inherited Mitochondrial Diseases

Resource links provided by NLM:

Further study details as provided by Repligen Corporation:

Estimated Enrollment:

Eligibility

Criteria

Mitochondrial Disease

Contacts and Locations

No Contacts or Locations Provided

More Information

No publications provided

Study ID Numbers:	RG2133-01
Study First Received:	May 7, 2003
Last Updated:	August 4, 2005
ClinicalTrials.gov Identifier:	NCT00060515 History of Changes
Health Authority:	United States: Food and Drug Administration

Additional relevant MeSH terms:

Metabolic Diseases
Mitochondrial Diseases

ClinicalTrials.gov processed this record on November 25, 2009